At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 38 enrolled
Drug / intervention
Inactivated Influenza Vaccine +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Open-Label, Study to Evaluate the Immunogenicity of One Dose of Live Attenuated Influenza Vaccine (LAIV) Compared to One Dose of Trivalent Inactivated Influenza Vaccine (IIV) in Adults 18-49 Years of Age
In Brief
A Phase 4 clinical trial evaluating Inactivated Influenza Vaccine and Live Attenuated Influenza Vaccine for Influenza. Completed, enrolled 38 participants.
Detailed Summary
This randomized, open-label, single-site study at Saint Louis University will enroll approximately 40 subjects who are healthy, 18 to 49 years old. Subjects will be randomized in a 1:1 fashion to receive either licensed trivalent FluMist containing (2010-2011 season appropriate), or licensed inactivated trivalent influenza vaccine (2010-2011 season appropriate) so that approximately 20 subjects will be randomized to receive LAIV, and 20 will receive IIV.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsInfluenza
Countries--
CollaboratorsMedImmune LLC
Timeline
Phase 4CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
Enrollment StartFeb 2011
Primary CompletionMay 2011
Study CompletionNov 2011
First PostedApr 2017
TodayJul 2026
First PostedApr 5, 2017
Enrollment StartFeb 24, 2011
Primary CompletionMay 13, 2011
Study CompletionNov 9, 2011
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 9.2 years ago
Interventions
Inactivated Influenza Vaccinebiological
Live Attenuated Influenza Vaccinebiological